Lixte Biotechnology Holdings Inc is a clinical-stage biopharmaceutical and proton cancer therapy company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies... Show more
Lixte Biotechnology Holdings, Inc. operates as a clinical-stage biopharmaceutical company historically focused on developing PP2A inhibitors to enhance chemotherapy and immunotherapy responses in solid tumors. Its lead asset, LB-100, targets multiple difficult-to-treat indications through investigator-sponsored and collaborative trials. The recent strategic transformation into AI energy infrastructure equipment and services, anchored by the acquisition of NOMAD, aims to diversify into the high-growth battery energy storage systems (BESS) market. This move leverages expertise in mobile, utility-grade solutions amid rising power needs from artificial intelligence infrastructure. Competitive positioning will depend on successful integration, technology differentiation in transportable storage, and the ability to maintain oncology progress without diluting focus.
Upcoming clinical data releases for LB-100 combinations represent significant potential inflection points. Preliminary efficacy results from the Phase 1b/2 trial in ovarian clear cell carcinoma (in combination with dostarlimab) and biomarker/response data from the metastatic microsatellite-stable colorectal cancer trial (with atezolizumab) are anticipated in the second half of 2026 or earlier, depending on enrollment timelines. Additional progression-free survival and objective response rate updates from the advanced soft tissue sarcoma trial (with doxorubicin) could further inform development plans. On the strategic front, closure of the NOMAD acquisition around July 1, 2026, followed by integration milestones and any subsequent partnership or contract announcements in the energy storage space, may influence sentiment. Capital allocation decisions post-raise, including potential further financing or pipeline prioritization, will also be closely watched. Limited analyst coverage means rating or target revisions are unlikely in the near term but could emerge if the dual-strategy execution gains traction.
The global push toward artificial intelligence is accelerating electricity demand from hyperscale data centers, creating structural tailwinds for battery energy storage solutions that address grid intermittency and peak shaving. Interest rate trajectories and inflation trends will affect capital costs for energy infrastructure projects, while government incentives and regulatory support for clean energy storage in various jurisdictions could accelerate adoption. In oncology, evolving immunotherapy landscapes and precision medicine trends continue to shape opportunities for novel combination therapies like LB-100. Geopolitical factors influencing supply chains for battery components and broader healthcare policy shifts around drug development timelines represent additional sensitivities for the company's legacy and emerging business lines.
Tickeron’s Trend Prediction Engine is an AI-powered forecasting tool that helps traders identify whether a stock, ETF, or other asset may move bullish, bearish, or sideways over the next week or month. It is designed to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a wide range of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality. Trend Prediction Engine
Looking to 2026 and beyond, the interplay between oncology clinical progress and the new AI energy infrastructure platform will define long-term positioning. Market expansion in mobile BESS could benefit from sustained AI compute growth and grid modernization efforts, while cost structure evolution will hinge on manufacturing scale and operational efficiencies post-acquisition. Margin sustainability in both segments will depend on successful commercialization pathways and competitive dynamics. Technology transitions in battery storage and potential regulatory developments around clinical trial endpoints or energy policy remain key variables. Capital allocation priorities, including further investment in the energy platform versus oncology, may shape investor perceptions of strategic focus. Consensus expectations are sparse given limited coverage, leaving room for sentiment to evolve based on execution milestones and sector-specific tailwinds in AI infrastructure and precision oncology.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Industry ElectricalProducts
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| PGBGX | 40.00 | 0.29 | +0.73% |
| Principal Blue Chip R5 | |||
| AMTYX | 11.37 | 0.06 | +0.53% |
| AB All Market Real Return Advisor | |||
| POIIX | 14.67 | -0.02 | -0.14% |
| Polen International Growth Institutional | |||
| FTUTX | 65.16 | -0.54 | -0.82% |
| Fidelity Advisor Telecommunications M | |||
| RPMIX | 11.26 | -0.12 | -1.05% |
| Royce Small-Cap Fund Instl | |||
A.I.dvisor indicates that over the last year, LIXT has been loosely correlated with PTHS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LIXT jumps, then PTHS could also see price increases.
| Ticker / NAME | Correlation To LIXT | 1D Price Change % | ||
|---|---|---|---|---|
| LIXT | 100% | N/A | ||
| PTHS - LIXT | 34% Loosely correlated | -7.96% | ||
| HYPD - LIXT | 31% Poorly correlated | N/A | ||
| NTLA - LIXT | 28% Poorly correlated | N/A | ||
| IBIO - LIXT | 28% Poorly correlated | N/A | ||
| BBIO - LIXT | 27% Poorly correlated | N/A | ||
More | ||||
| Ticker / NAME | Correlation To LIXT | 1D Price Change % |
|---|---|---|
| LIXT | 100% | N/A |
| Electrical Products industry (48 stocks) | 4% Poorly correlated | -1.46% |
| Producer Manufacturing industry (353 stocks) | -5% Poorly correlated | -0.69% |
The 50-day moving average for LIXT moved above the 200-day moving average on June 01, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Momentum Indicator moved above the 0 level on June 29, 2026. You may want to consider a long position or call options on LIXT as a result. In of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where LIXT advanced for three days, in of 209 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 95 cases where LIXT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The 10-day RSI Indicator for LIXT moved out of overbought territory on June 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 26 similar instances where the indicator moved out of overbought territory. In of the 26 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 44 cases where LIXT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for LIXT turned negative on June 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LIXT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
LIXT broke above its upper Bollinger Band on June 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. LIXT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.367) is normal, around the industry mean (12.020). P/E Ratio (0.000) is within average values for comparable stocks, (250.078). LIXT's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.720). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (23.677).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LIXT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock worse than average.